IGFBP7
Recombinant Human IGF-Binding Protein 7 (Fc Tag)

Catalog No.	CRH693A-Fc CRH693B-Fc	**Quantity:**	20 µg 50 µg

Alternate Names: Insulin-like growth factor-binding protein 7, IBP-7, IGF-binding protein 7, IGFBP-7, IGFBP-rP1, MAC25 protein, PGI2-stimulating factor, Prostacyclin-stimulating factor, Tumor-derived adhesion factor, TAF

Description: Insulin like growth factor binding protein 7 (IGFBP7) is a member of the IGFBP family. It has been identified in colorectal adenocarcinoma cell lines. IGFBPs are clearly distinct but are sharing regions with strong homology. All members of the IGFBP family bind IGF-I and IGF-II with about equal affinity. Insulin-like growth factor (IGF) binding proteins (IGFBPs) have been shown to either inhibit or enhance the action of IGF, or act in an IGF-independent manner in the prostate. IGFBP7 could inhibit cell growth, decrease soft agar colony formation activity and induce apoptosis in RKO and SW62 cells. There is mounting evidence that the structure of the IGFBP proteins plays a key role in the regulation of IGF bioavailability, by modulating its molecular size, capillary membrane permeability, target tissue specificity, cell membrane adherence and IGF affinity.

UniProt ID: Q16270

Protein Construction: A DNA sequence encoding the human IGFBP7 (Met 1-Leu 282) was fused with the Fc region of human IgG1 at the C-terminus.

Source: HEK293 Cells

Formulation: Lyophilized from sterile PBS, pH 7.4
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.

Molecular Weight: The secreted rhIGFBP7/Fc is a disulfide-linked homodimer. The reduced monomer consists of 497 aa with a predicted MW of 53.5 kDa and migrates at ~65-70 kDa in SDS-PAGE under reducing conditions.

Purity: > 85 % as determined by SDS-PAGE.

Endotoxin Level: < 1.0 EU per µg of the protein as determined by the LAL method

Biological Activity: Measured by its binding ability in a functional ELISA .
1. Immobilized IGFBP7-Fc at 20 µg/ml (100 µl/well) can bind biotinylated human IGF2-nusa. The EC50 of biotinylated human IGF2-nusa is 0.06 µg/ml .
2. Immobilized human CCL21 at 2 µg/ml (100 µl/well) can bind human IGFBP7-Fc with a linear ranger of 0.16-4 µg/ml.

Predicted N-terminal: Ser 27

Reconstitution: **Centrifuge vial prior to opening.** Add sterile distilled water to a concentration of 0.1 mg/mL and gently pipette the solution up and down the sides of the vial.
DO NOT VORTEX. Allow several minutes for complete reconstitution.

Cell Sciences®
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com

Storage & Stability: Stable for up to 1 year from date of receipt at -20°C to -80°C
After reconstitution, store working aliquots at -20°C to -80°C.
Avoid repeated freeze-thaw cycles.

SDS-PAGE



NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

Cell Sciences®
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com